NASDAQ:SHPG - Shire Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
+0.30 (1.20%)
Get New Shire Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SHPG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SHPG

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Shire in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $179.20.

This chart shows the closing price for SHPG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Shire. This rating has held steady since December 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/20/2018Cantor FitzgeraldSet Price TargetBuy$222.00Low
12/20/2018William BlairDowngradeOutperform ➝ Market PerformLow
12/11/2018SunTrust BanksDowngradeBuy ➝ HoldLow
12/4/2018B. RileyReiterated RatingBuyHigh
10/23/2018Royal Bank of CanadaSet Price TargetBuy$195.00Low
9/7/2018Berenberg BankDowngradeBuy ➝ HoldLow
9/4/2018Evercore ISIDowngradeOutperform ➝ Market Perform$196.00Low
9/4/2018Sanford C. BernsteinDowngradeOutperform ➝ Market PerformLow
7/31/2018Cantor FitzgeraldSet Price TargetBuy$222.00Low
7/19/2018Royal Bank of CanadaSet Price TargetBuy$188.00Low
5/11/2018Kepler Capital MarketsReiterated RatingBuy ➝ BuyLow
5/8/2018Royal Bank of CanadaReiterated RatingBuyLow
4/29/2018BTIG ResearchReiterated RatingBuy$195.00Low
4/22/2018Royal Bank of CanadaSet Price TargetBuy$186.00Low
4/19/2018B. RileyBoost Price TargetBuy$200.00Low
4/16/2018Cantor FitzgeraldSet Price TargetBuy$222.00Medium
4/9/2018Cantor FitzgeraldSet Price TargetBuy$222.00Low
3/28/2018Bank of AmericaReiterated RatingBuyHigh
3/28/2018Cantor FitzgeraldSet Price TargetBuy$222.00High
3/7/2018Cantor FitzgeraldSet Price TargetBuy$222.00Low
2/20/2018SunTrust BanksLower Price TargetBuy$190.00Medium
2/20/2018JPMorgan Chase & Co.Reiterated RatingOverweight ➝ NeutralMedium
2/19/2018JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$200.00 ➝ $150.00High
2/16/2018Royal Bank of CanadaLower Price TargetOutperform$181.00Low
2/16/2018B. RileyLower Price TargetBuy ➝ Buy$201.00 ➝ $181.00Low
2/15/2018Royal Bank of CanadaReiterated RatingBuyLow
2/14/2018Cantor FitzgeraldSet Price TargetBuy$222.00Medium
2/14/2018Sanford C. BernsteinUpgradeMarket Perform ➝ OutperformMedium
2/5/2018Royal Bank of CanadaSet Price TargetBuy$192.00Low
2/5/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$236.00 ➝ $237.00High
1/5/2018CowenSet Price TargetBuy$225.00Low
1/3/2018Cantor FitzgeraldSet Price TargetBuy$222.00Low
1/3/2018Piper Jaffray CompaniesReiterated RatingHoldLow
12/27/2017Cantor FitzgeraldSet Price TargetBuy$222.00Low
12/20/2017Liberum CapitalReiterated RatingBuy ➝ HoldMedium
12/5/2017Cantor FitzgeraldSet Price TargetBuy$222.00Medium
11/16/2017Royal Bank of CanadaReiterated RatingBuyN/A
11/16/2017Cantor FitzgeraldSet Price TargetBuy$222.00N/A
11/14/2017Liberum CapitalUpgradeHold ➝ BuyN/A
10/30/2017FBR & Co.Reiterated RatingBuy$201.00N/A
10/29/2017CowenSet Price TargetBuy$225.00N/A
10/27/2017Cantor FitzgeraldReiterated RatingBuy$222.00N/A
10/27/2017Piper Jaffray CompaniesReiterated RatingHold$160.00N/A
10/19/2017FBR & Co.Initiated CoverageBuy ➝ Buy$201.00N/A
10/11/2017Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$213.00N/A
10/8/2017Stifel NicolausReiterated RatingBuy$245.00N/A
10/2/2017Royal Bank of CanadaReiterated RatingBuy$213.00Low
9/14/2017Cantor FitzgeraldReiterated RatingBuy$222.00Low
8/21/2017Cantor FitzgeraldReiterated RatingBuy$222.00Low
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$196.00Medium
8/15/2017Cantor FitzgeraldSet Price TargetBuy$222.00Low
8/11/2017BarclaysDowngradeOverweight ➝ Equal WeightLow
8/9/2017Jefferies Financial GroupReiterated RatingHold$216.00 ➝ $206.00Low
8/4/2017Royal Bank of CanadaSet Price TargetBuy$213.00Low
7/26/2017Piper Jaffray CompaniesSet Price TargetHold$159.00Medium
7/17/2017BTIG ResearchReiterated RatingBuy$242.00Low
7/13/2017Sanford C. BernsteinReiterated RatingMarket Perform$210.00Low
7/12/2017Stifel NicolausReiterated RatingBuy$245.00Low
7/11/2017Cantor FitzgeraldSet Price TargetBuy$222.00Medium
7/1/2017Cantor FitzgeraldSet Price TargetBuy$222.00Low
6/16/2017Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$222.00Low
6/9/2017Stifel NicolausLower Price TargetBuy$250.00 ➝ $245.00Low
6/9/2017Jefferies Financial GroupReiterated RatingBuy ➝ Buy$239.00 ➝ $216.00Low
6/8/2017Royal Bank of CanadaSet Price TargetBuy$218.00Low
6/1/2017Liberum CapitalDowngradeBuy ➝ HoldLow
5/31/2017CowenReiterated RatingOutperform$325.00Low
5/25/2017Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$209.22 ➝ $161.09Low
5/18/2017Royal Bank of CanadaSet Price TargetBuy$221.00Low
4/20/2017Jefferies Financial GroupSet Price TargetBuy$239.00Low
4/18/2017Royal Bank of CanadaReiterated RatingOutperform$221.00Medium
4/17/2017The Goldman Sachs GroupBoost Price TargetOverweight$202.00 ➝ $214.00Low
4/14/2017The Goldman Sachs GroupReiterated RatingConviction-BuyN/A
3/21/2017The Goldman Sachs GroupReiterated RatingFocus ListLow
3/18/2017Jefferies Financial GroupSet Price TargetBuy$239.00Low
3/14/2017Royal Bank of CanadaReiterated RatingBuy$221.00Low
3/9/2017Liberum CapitalInitiated CoverageBuy ➝ BuyLow
3/7/2017BarclaysInitiated CoverageOverweightN/A
2/17/2017Jefferies Financial GroupSet Price TargetBuy$248.00 ➝ $239.00N/A
2/17/2017GuggenheimReiterated RatingNeutralN/A
12/23/2016BTIG ResearchReiterated RatingBuy$242.00N/A
12/6/2016UBS GroupDowngradeBuy ➝ HoldN/A
12/2/2016Societe GeneraleInitiated CoverageBuyN/A
11/14/2016SVB LeerinkSet Price TargetBuy$198.00N/A
11/11/2016Jefferies Financial GroupSet Price TargetBuy$248.00N/A
11/11/2016Royal Bank of CanadaReiterated RatingOutperform$235.00N/A
11/7/2016JPMorgan Chase & Co.Reiterated RatingOverweightN/A
11/3/2016CitigroupReiterated RatingBuyN/A
11/3/2016Jefferies Financial GroupReiterated RatingBuy$248.00N/A
11/2/2016Deutsche Bank AktiengesellschaftReiterated RatingBuyN/A
11/1/2016BTIG ResearchReiterated RatingBuy$242.00N/A
10/24/2016JPMorgan Chase & Co.Reiterated RatingOverweightN/A
10/23/2016BNP ParibasReiterated RatingBuyN/A
10/17/2016JPMorgan Chase & Co.Reiterated RatingOverweightN/A
10/16/2016The Goldman Sachs GroupReiterated RatingBuyN/A
10/8/2016Shore CapitalReiterated RatingBuyN/A
10/3/2016JPMorgan Chase & Co.Reiterated RatingOverweightN/A
10/1/2016SVB LeerinkReiterated RatingBuyN/A
10/1/2016Piper Jaffray CompaniesSet Price TargetHold$201.00N/A
9/28/2016Shore CapitalReiterated RatingBuyN/A
9/27/2016CitigroupReiterated RatingBuyN/A
9/26/2016JPMorgan Chase & Co.Reiterated RatingOverweightN/A
(Data available from 9/24/2016 forward)

News Sentiment Rating

0.06 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Shire logo
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $179.20
Low: $179.20
High: $179.20

50 Day Range

MA: $179.20
Low: $179.20
High: $179.20

52 Week Range

Now: $179.20
Low: $123.73
High: $182.47



Average Volume

2,212,143 shs

Market Capitalization

$54.71 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Shire?

The following equities research analysts have issued reports on Shire in the last twelve months:
View the latest analyst ratings for SHPG.

What is the current price target for Shire?

0 Wall Street analysts have set twelve-month price targets for Shire in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Shire in the next year.
View the latest price targets for SHPG.

What is the current consensus analyst rating for Shire?

Shire currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SHPG.

How do I contact Shire's investor relations team?

Shire's physical mailing address is BLOCK 2 MIESIAN PLAZA 50-58 BAGGOT STREET LOWER, Dublin L2, D02. The biopharmaceutical company's listed phone number is 353-1609-6000 and its investor relations email address is [email protected] The official website for Shire is